Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Hepatoblastoma 1

Interventions

Cisplatin 8Carboplatin 8X-Rays 7Specimen Handling 7Phantoms, Imaging 7Magnetic Resonance Spectroscopy 6Cyclophosphamide 6sodium thiosulfate 5Vincristine 5Nuclear Medicine Department, Hospital 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Doxorubicin 5Biopsy 5Melphalan 4Irinotecan 4Fluorouracil 4fludarabine 3Thiotepa 3Oxaliplatin 3Mesna 3Gemcitabine 3Filgrastim 3Busulfan 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatoblastoma × imetelstat × Gastrointestinal × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡